Meeting
2023 ASCO Annual Meeting
Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer.
Authors
Milou Schuurbiers
Department of pulmonary diseases, Radboud university medical center, Nijmegen, Netherlands
Milou Schuurbiers , Christopher Gareth Smith , Koen Hartemink , Robert Rintoul , Kim Monkhorst , Daan van den Broek , Nitzan Rosenfeld , Michel van den Heuvel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8535)
DOI
10.1200/JCO.2023.41.16_suppl.8535
Abstract #
8535
Poster Bd #
162
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.
First Author: Davina Gale
Poster
2022 ASCO Annual Meeting
Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non–small cell lung cancers.
First Author: Xiaoru Tian
Poster
2022 ASCO Annual Meeting
Utilization of cell-free DNA fragmentomics in minimal residual disease detection for non-small cell lung cancer.
First Author: Rong Yin
Poster
2021 ASCO Annual Meeting
Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.
First Author: Damien Vasseur